"Azafaros has been impressive in its execution with nizubaglustat poised to begin Phase 3 clinical development and the potential to significantly improve the lives of NPC and GM1/GM2 patients."
"Azafaros exemplifies the kind of science-driven, mission-focused company we seek to back. Nizubaglustat has the potential to fundamentally change the treatment landscape for rare genetic diseases."
Azafaros, a Netherlands-based clinical-stage biotech firm focused on rare lysosomal storage disorders, has successfully completed a â¬132M Series B funding round aimed at advancing its drug development, specifically for conditions like Niemann-Pick Type C (NPC) and GM1/GM2 diseases. Led by Jeito Capital and co-led by Forbion Growth, the investment underscores a strong belief in the potential of Azafaros's pipeline, particularly its candidate nizubaglustat, which is poised for Phase 3 trials. New board members from leading investors will help steer the company through its next phases in clinical development.
Read at Silicon Canals
Unable to calculate read time
Collection
[
|
...
]